Literature DB >> 21327396

Progressive multifocal leukoencephalopathy following chemotherapy for lung cancer.

Antonio Palmieri1, L Valentinis, S Bazzano, A Baldi, F Orlando, S Tenaglia, S D'Anna.   

Abstract

Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system caused by the JC virus infection and with a frequent lethal outcome. PML usually occurs in immunocompromised subjects, such as HIV-positive individuals, as well as in other conditions characterized by depletion of cellular immunity, including hematological malignancies, autoimmune diseases, and immunomodulatory therapies. We describe the case of a 76-year-old man affected by advanced non-small cell lung cancer who developed PML after six cycles of carboplatin/gemcitabine therapy, during which a transitory leucopenia developed. The patient deceased a few months after the onset of the symptoms. Chemotherapy appears to be uncommon, but definite condition associated to PML.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21327396     DOI: 10.1007/s10072-011-0494-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  8 in total

1.  Progressive multifocal leuko-encephalopathy; a hitherto unrecognized complication of chronic lymphatic leukaemia and Hodgkin's disease.

Authors:  K E ASTROM; E L MANCALL; E P RICHARDSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

2.  JC virus DNA load in patients with and without progressive multifocal leukoencephalopathy.

Authors:  I J Koralnik; D Boden; V X Mai; C I Lord; N L Letvin
Journal:  Neurology       Date:  1999-01-15       Impact factor: 9.910

3.  Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer.

Authors:  S M Lee; L E James; W Qian; S Spiro; T Eisen; N H Gower; D R Ferry; D Gilligan; P G Harper; J Prendiville; M Hocking; R M Rudd
Journal:  Thorax       Date:  2008-09-11       Impact factor: 9.139

Review 4.  Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies.

Authors:  Eugene O Major
Journal:  Annu Rev Med       Date:  2010       Impact factor: 13.739

Review 5.  Gemcitabine and carboplatin in combination for the treatment of advanced, metastatic, non-small cell lung cancer.

Authors:  Sylke Nagel; Raffaele Califano; Nicholas Thatcher; Fiona Blackhall
Journal:  Expert Opin Pharmacother       Date:  2007-12       Impact factor: 3.889

Review 6.  Progressive multifocal leukoencephalopathy in individuals with minimal or occult immunosuppression.

Authors:  Sarah Gheuens; Gerald Pierone; Patrick Peeters; Igor J Koralnik
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-10-14       Impact factor: 10.154

Review 7.  Progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. A review of the literature with a report of sixteen cases.

Authors:  J R Berger; B Kaszovitz; M J Post; G Dickinson
Journal:  Ann Intern Med       Date:  1987-07       Impact factor: 25.391

8.  Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study.

Authors:  Frederik Neess Engsig; Ann-Brit Eg Hansen; Lars Haukali Omland; Gitte Kronborg; Jan Gerstoft; Alex Lund Laursen; Court Pedersen; Christian Backer Mogensen; Lars Nielsen; Niels Obel
Journal:  J Infect Dis       Date:  2009-01-01       Impact factor: 5.226

  8 in total
  2 in total

1.  Drug-associated progressive multifocal leukoencephalopathy: a clinical, radiological, and cerebrospinal fluid analysis of 326 cases.

Authors:  Roderick P P W M Maas; Annemarie H G Muller-Hansma; Rianne A J Esselink; Jean-Luc Murk; Clemens Warnke; Joep Killestein; Mike P Wattjes
Journal:  J Neurol       Date:  2016-07-11       Impact factor: 4.849

2.  Progressive multifocal leukoencephalopathy associated with chemotherapy induced lymphocytopenia in solid tumors - case report of an underestimated complication.

Authors:  Patrick Mayr; Mathias Lutz; Maximilian Schmutz; Jens Hoeppner; Friederike Liesche-Starnecker; Jürgen Schlegel; Jochen Gaedcke; Rainer Claus
Journal:  Front Oncol       Date:  2022-08-02       Impact factor: 5.738

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.